Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Corporate Update (June 2020)

42 slides from Windtree Therapeutics's corporate update, Jun 4, 2020

  1. Slide 1: Windtree Therapeutics Company Overview & Business Update Call

    Windtree Therapeutics Company Overview & Business Update Call June 4, 2020 WINDTREE (NAS IT) THERAPEUTICS

  2. Slide 2: Forward-looking Statements

    Forward-looking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company

  3. Slide 3: Windtree Therapeutics

    Windtree Therapeutics Windtree Therapeutics is a clinical-stage biopharmaceutical and medical device company with multiple advanced cl FDA Fast Track Designation Potential for Breakthrough designation FDA, EMA Orphan Drug for RDS FDA Fast Track Designation, Orphan Drug ZWINDTR GR ex ‘al programs spa

  4. Slide 4: Strategy for Value Creation

    Strategy for Value Creation Planned Milestones = Three clinical programs focused on significant markets with unmet needs = Multiple clinical and business milestones which have the potential to be catalysts Istaroxime Data, Early Cardiogenic Shock Study Yate A Data, staroxime £0P2 Mitginto (transitio

  5. Slide 5: Istaroxime

    Istaroxime Dual Mechanism, SERCA2a Activator for the Treatment of Acute Heart Failure and .. Early Cardiogenic Shock

  6. Slide 6: Heart Failure

    Heart Failure - The prevalence of HF is high and on the rise (as is mortality) # of Patients: 6M (U.S.) | 18M (Worldwide) Hospital Admissions: #1 cause of hospitalization in patients> 65 years old (U.S.) > 1.3M admissions annually (U.S.) ~1.5M admissions annually (E.U.) Inpatient Mortality: Up to 7%

  7. Slide 7: Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need

    Acute Heart Failure - Significant Healthcare Issue with Significant Unmet Clinical Need = There has not been meaningful new pharmacologic advancements in acute heart failure for decades = Current approaches to acutely improve cardiac function are associated with unwanted effects: Heart rhythm distur

  8. Slide 8: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart. Dual Mechanism of At Inhibition of the sodium- e Stimulation of SERCA2a activity enhances potassium pump and effects on m calcium reuptake resulting in th

  9. Slide 9: Istaroxime AHF Phase 2b Study - Summary

    Istaroxime AHF Phase 2b Study - Summary Primary = Change in E/e’ at 24 hours (non-invasive estimate of PCWP) measured by Endpoint: echocardiography Trial Design: = Adult patients hospitalized for recurrent AHF (dyspnea plus need for IV furosemide 2 40mg) = 120 patients = Multicenter, double blind, p

  10. Slide 10: Primary Endpoint — Significant Changes in E/e' Ratio and Stroke Volume

    Primary Endpoint — Significant Changes in E/e' Ratio and Stoke Volume istaroxime 0.5 g/kg/min vs. placebo istaroxime 1.0 g/kg/min vs. placebo 20 20 10 10 00 co a0 40 ° £20 3 230 > e390 3 Efe’ 3, 50 50 Infusion period 3 infu - : < 60 as £0 pralues <0.034 70 20 Beene Ghours —28hous —ABhours eeeine how

  11. Slide 11: Systolic Blood Pressure Maintained or Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Maintained or Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 g/kg/min vs. placebo istaroxime 1.0 yg/kg/min vs. placebo 2 9 = ° E a ae Ea = 2 E3 5 SBP 5 : Se 53 ait | | |} ff 6 Infusion period oe ee ge ge * =0.011, ** FF FF oF oF OS * value =0.0

  12. Slide 12: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Create a strong phase 3 and partnership position - * Execute an additional study that is expected to complete Phase 2 and inform Phase 3 - 300 patients, 75 centers globally (estimates) * Leverage characteristics in a target population that most

  13. Slide 13: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output No Satisfactory Pharmacologic

  14. Slide 14: Istaroxime SBP Change from Baseline Phase 2a and 2b Dose Groups

    Istaroxime SBP Change from Baseline to 6 or 24 Hours from the Phase 2a and 2b Dose Groups Istaroxime has the potential to improve blood pressure and organ perfusion in patients with AHF 10.0 8.0 6.0 4.0 2.0 0.0 2a Study 2b Study 2a Study 2b Study 2a Study SBP Mean Change 0.5 pg/kg/min 1.0 pg/kg/min

  15. Slide 15: Istaroxime — Early Cardiogenic Shock — Next Steps

    Istaroxime — Early Cardiogenic Shock — Next Steps + Initiate a study in early cardiogenic shock while we are preparing for the larger phase 2b acute heart failure study - ~60 patients conducted in the Europe and US - Start mid-2020 with data expected in Q2 2021 + Phase 2 clinical program suggests a

  16. Slide 16: Pre-Clinical Programs

    Pre-Clinical Programs Novel Oral SERCA2a Activators for HF + Acute Pulmonary Platform The Company also has early exploratory research programs to identify potential product candidates including: Cardiovascular Selective SERCA2a Dual Mechanism Compounds Activators for Heart Failure * Oral &i.v. thera

  17. Slide 17: COVID-19 Lung Injury Treatment

    COVID-19 Lung Injury Treatment Synthetic KL4 Surfactant for the Treatment of Lung Injury in COVID-19 Patients

  18. Slide 18: COVID-19 and ARDS Have A Significant Negative Impact On Surfactant Related Lung Function

    COVID-19 and ARDS Have A Significant Negative Impact On Surfactant Related Lung Function Uses angiosten- ACE2is a surface molecule on Damaged Type 2 cells Increased likelihood of converting enzyme 2 alveolar Type 2 cells of lungs, results in impaired mechanical ventilation (ACE2) for entry into the

  19. Slide 19: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study

    KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza = Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 surfactant tre

  20. Slide 20: Surfactant Administration In Severe COVID-19 Lung Injury

    Surfactant Administration In Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits = We believe our synthetic KL4 surfactant may have the potential to mitigate surfactant deficiency and resist the Si widespread surfactant destruction that can occur as a aA result of COVID-19

  21. Slide 21: Clinical Proposal: Lucinactant for Treatment of COVID-19

    Clinical Proposal: Lucinactant (KL4 Surfactant) For The Treatment of COVID-19 Initial phase 2 study will be to demonstrate changes in physiological parameters in COVID-19 associated lung injury and ARDS INDTREE Up to 30 patients from 4-5 US sites (lead by institutions in Boston & Durham, NC) Dosing

  22. Slide 22: Evidence of KL4 Surfactant Potential Utility in COVID-19

    Evidence of KL4 Surfactant Potential Utility in COVID-19— Demonstrated Utility Across Various Respiratory Distress Extensive Studies in * 13 studies for intratracheal administration including RDS, BPD, acute Acute Lung Conditions: hypoxemic respiratory failure and adults with ARDS = 2,148 patients e

  23. Slide 23: AEROSURF

    AEROSURF® Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System for the Treatment of RDS

  24. Slide 24: Respiratory Distress Syndrome (RDS) Current Treatment Pathways

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and gas exchange = Physicians have to choose between invasive surfactant de

  25. Slide 25: AEROSURF - Potential to Impact the Clinical Course of RDS

    AEROSURF® - Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment Improved Long-Term Respiratory Outcomes Study results across each Parameters of these important parameters show evidence of a potential impact on the clinical cours

  26. Slide 26: Mitigating Risks and Strengthening Our Approach

    Mitigating Risks and Strengthening Our Approach Program Evolution Completed three phase 2a and 2b trials = = Execute a small (n=~80 - 90) Bridging Study to transition to EOP2 / Phase 3 Efficacy in reducing nCPAP failure and the need for intubation = = Demonstrate the new ADS works and supplement pha

  27. Slide 27: Summary

    Summary

  28. Slide 28: Business Development Focus

    Business Development Focus We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 — Project Financing Model Heart Failure Portfolio Partner — Global Mid-term (Data & EOP2) R

  29. Slide 29: May 2020 Public Offering Overview

    May 2020 Public Offering Overview * $23.0 million public offering of 3,172,413 units at a price of $7.25 per unit including full exercise of the underwriter over-allotment option * Each unit consists of one share of common stock and one warrant to purchase one share of common stock at an exercise pr

  30. Slide 30: Financial Summary & Capitalization

    Financial Summary & Capitalization = Cash & Equivalents of ~ $35 million as of closing of public offering = Debt: $4.6M bank credit facility currently due in March 2022 * Guaranteed by Lee’s Pharmaceutical Holdings Ltd. (SEHK:950) Common Equivalents Secu S Common Stock 16,869,808 Options (WAEP $17.6

  31. Slide 31: Multiple Development and Business Activities Create a Robust Outlook of Potential Milestones

    Multiple Development and Business Activities Create a Robust Outlook of Potential Milestones 2020 / 1H 2021 Planned Events Strategy for Value Creation | isn ped MAES DS 5 + AEROSURF bridge study start, * Three clinical programs focused on significant markets with unmet needs inten , = Multiple clini

  32. Slide 32: Windtree Therapeutics

    Windtree Therapeutics “Striving to deliver Hope for a Lifetime!” we GS winDTtREE

  33. Slide 33: Appendix

    Appendix Se wINDTREE we" .

  34. Slide 34: Cardiac Output, Blood Pressure and Renal Function are Critical Factors in Managing AHF

    Cardiac Output, Blood Pressure and Renal Function are Critical Factors in Managing AHF Patients and Their Outcomes Early drop in systolic blood pressure and worsening renal function in acute heart 2 , <8 failure: renal results of Pre-RELAX-AHF In-Hospital Mortality Rates by Admission Baie pesca palh

  35. Slide 35: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study Primary Endpoint: PCWP Significant Improvements = Multicenter, double blind, placebo-controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: ° LVEF < 35% © SBP 90-150 mmHg =

  36. Slide 36: Istaroxime Phase 2b Study

    Istaroxime Phase 2b Study Favorable Profile Observed with 24-hour Holter Monitoring Clinically significant arrhythmias Clinically significant arrhythmias 120% —105% 105% 105% siceae 10.0% 200% 200% 20.0% 8.0% 6.0% 50% 0.0% 10.0% 40% 2.4% 2.4% ae ON | i 20% 5.0% on oo Baseline Day! (infusion) Baselin

  37. Slide 37: Istaroxime Phase 2b Adverse Events

    Istaroxime Phase 2b Adverse Events istaroxime 0.5 istaroxime 1.0 Pooled placebo (n=39) Alladverse events Adverse events leat discontinuation gto Serious adverse events Cardiac death fenic shock Cardiac failure Renal embolism Transient ischemic attack Hyperventilation Hypotension Adverse Drug Reactio

  38. Slide 38: Respiratory Distress Syndrome (RDS) Current Treatment Pathways

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf

  39. Slide 39: Windtree Technology Platform - AEROSURF

    Windtree Technology Platform - AEROSURF® Proprietary Synthetic KL4 Surfactant + Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLa surfactant (intratracheal instillate) ability to aerosolize KLa surfactant for RDS approved by the FDA Lyo

  40. Slide 40: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® Surfactant Therapy nCPAP Respiratory Support RISKS respiration Surfactant therapy delivers near-immediate clinical improvement Reversing surfactant deficientey.has /a profound positive impact on \ BPD Infection, ventilator-induced pneumonia “Avoids exposure to t

  41. Slide 41: References Supporting Utilization of KL4 Surfactant for the Treatment of Lung Injury

    References Supporting Utilization of KL, Surfactant for the Treatment of Lung Injury Hoffmann, MH. Kleine Weber, etal. (2020). "The novel coronavirus 2019 (2019-nCoV) uses the SARS-corcnavirus receptor ACE2 andthe cellular protease TMPRSS2 for entry into target cellsi0.1101/2020.01.31.929042." bioRk

  42. Slide 42: Surfactant in ARDS References

    Surfactant in ARDS References 1. Gregory TJ, Steinberg KP, Spragg R, Gadek JE, Hyers TM, Longmore Wi, et al. Bovine surfactant therapy for patients with acute respiratory distresssyndrome.Am J Respir Crit Care Med. 1997;155:1309-1315. 2. Wiedemann H, Baughman R, de BoisblancE,et al.,A multi centered

Windtree Therapeutics — Corporate Update (June 2020) on 6ix